Latest on Ultrasound Renal Denervation

Published: 22 June 2022

  • Views:

    Views Icon 7871

  • Likes:

    Heart Icon 7
  • episode_image
    1h 4m 58s
    Part 7 | Session 1 ACC 2022 Symposium
    Michael Weber, Felix Mahfoud, Ajay J Kirtane, Michael Bloch
  • episode_image
    59m 32s
    Part 7 | Session 2 TCT 2021 Symposium
    Chandan Devireddy, Ajay J Kirtane, Felix Mahfoud, Naomi Fisher
Average (ratings)
No ratings
Your rating

Overview

Ultrasound Renal Denervation (uRDN) is an innovative therapy option for the treatment of uncontrolled hypertension. uRDN therapy is delivered in a minimally invasive procedure that may lower high blood pressure by treating overactive renal nerves with ultrasound energy.

 

This page provides an overview of uRDN technology and the latest evidence from its associated RADIANCE clinical program.

 

The PARADISETM System is Limited to Investigational Use Only in the United States. Approved for distribution in CE mark countries only.
This educational content is supported by:

What you will learn:

  • How uRDN works and its potential benefits for patients suffering from uncontrolled hypertension
  • The clinical evidence supporting uRDN and its implications for the field of hypertension
  • The process for building a uRDN centre and therapy network

This page is designed for:

  • Interventional cardiologists
  • General cardiologists
  • Hypertension specialists
  • Nephrologists
  • Interventional radiologists

More from this programme

Part 1

The Science of uRDN

Understand the science of Ultrasound Renal Denervation (uRDN) and its potential benefits for the treatment of uncontrolled hypertension
5 sessions
The Science of Ultrasound Renal Denervation: Introduction Watch now
Ultrasound Technology – Its Development and Unique Characteristics: Andy Wu Watch now
Ultrasound Renal Denervation Preclinical Evidence: Dr Michael Joner Watch now
RDN Procedure with Ultrasound Technology: Prof Felix Mahfoud Watch now
Panel Discussion: All Watch now

Part 2

The Evidence for uRDN

3 sessions
The Paradise uRDN System: Dr Andrew Sharp Watch now
uRDN Clinical Evidence - What does this mean for the field?: Prof Felix Mahfoud Watch now
How to build uRDN centre / therapy pathway: Prof Roland Schmieder Watch now

Part 3

From Proof to Practice – Treating Hypertension With uRDN

3 sessions
Introduction and "Ultrasound RDN - Reviewing the Latest Clinical Results" : Atul Pathak Watch now
"Ultrasound RDN - Reviewing the Latest Clinical Results" : Joost Daemen Watch now
"How to build Interventional HTN Therapy/Practice": Joachim Weil Watch now

Part 4

RADIANCE II Pivotal Trial for Paradise Ultrasound Renal Denervation System in Patients With Hypertension

TCT 2022 Satellite Symposium.
2 sessions
RADIANCE II Pivotal Trial Watch now
Ultrasound Renal Denervation (uRDN) – Leading with Evidence and Preparing for What Comes Next Watch now

Part 5

Results From the Latest Clinical Trials

Deep dive into the latest information on the RADIANCE-HTN trials
4 sessions
EuroPCR 2022 – Patient-Level Pooled Analysis of RADIANCE-HTN SOLO and TRIO Trials Watch now
TCT 2021 – RADIANCE-HTN TRIO 6 months Outcomes vs Sham Procedure for Resistant Hypertension Watch now
ACC 2021 – RADIANCE-HTN TRIO Trial Results with Ajay Kirtane Watch now
EuroPCR 2020 – Crossover Results From the RADIANCE-HTN SOLO Trial Watch now

Part 6

Patient Perspective & Provider Referral Development

Understand patient preference and referral development
1 session
Ultrasound Renal Denervation – Patient Perspective, Referral Development Watch now

Part 7

Discussion With Experts

2 sessions
ACC 2022 Symposium Watch now
TCT 2021 Symposium Watch now

Faculty Biographies

Ajay J Kirtane

Ajay J Kirtane

Professor of Clinical Medicine

Ajay J Kirtane, is Professor of Medicine at the Columbia University Medical Center (CUMC) and Director of the Cardiac Catheterization Laboratories at NewYork-Presbyterian (NYP) Hospital / CUMC. Dr. Kirtane is an internationally-renowned leader in Interventional Cardiology, specializing in the care of patients with complex coronary and peripheral vascular disease.

 

In addition to his clinical commitments, Ajay has a strong interest in clinical education and research, serving as Chief Academic Officer of Columbia Interventional Cardiovascular Care. He is a director of the Cardiovascular Research Foundation’s Transcatheter Cardiovascular Therapeutics conference, has served as a director of several international, national, and regional educational conferences, and has participated on the program committees for the scientific sessions of both the American College of Cardiology and American Heart Association. Ajay’s research…

View full profile